[1]
|
Stute P, Wildt L, Neulen J. The impact of micronized progesterone on breast cancer risk: a systematic review[J]. Climacteric, 2018, 21: 111-122. doi: 10.1080/13697137.2017.1421925 |
[2]
|
Boardman HMP, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women[J]. Cochrane Database Syst Rev, 2015, (3): CD002229. doi: 10.1002/14651858.CD002229.pub3/pdf/standard |
[3]
|
陈蓉, 郁琦, 徐克惠, 等. 中国14家医院妇科门诊40~60岁患者绝经相关特征的调查[J]. 中华妇产科杂志, 2013, 48: 723-727. doi: 10.3760/cma.j.issn.0529-567x.2013.10.002 |
[4]
|
Cintron D, Lipford M, Larrea-Mantilla L, et al. Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis[J]. Endocrine, 2017, 55: 702-711. doi: 10.1007/s12020-016-1072-9 |
[5]
|
Sarri G, Pedder H, Dias S, et al. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause[J]. BJOG, 2017, 124: 1514-1523. doi: 10.1111/1471-0528.14619 |
[6]
|
Geiger PJ, Eisenlohr-Moul T, Gordon JL, et al. Effects of perimenopausal transdermal estradiol on self-reported sleep, independent of its effect on vasomotor symptom bother and depressive symptoms[J]. Menopause, 2019, 26: 1318-1323. doi: 10.1097/GME.0000000000001398 |
[7]
|
Zhang L, Ruan X, Cui Y, et al. Menopausal Symptoms and Associated Social and Environmental Factors in Midlife Chinese Women[J]. Clin Interv Aging, 2020, 15: 2195-2208. doi: 10.2147/CIA.S278976 |
[8]
|
Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause[J]. Menopause, 2019, 26: 431-453. doi: 10.1097/GME.0000000000001221 |
[9]
|
Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women[J]. Cochrane Database Syst Rev, 2016, (8): CD001500. http://www.ncbi.nlm.nih.gov/pubmed/14583935 |
[10]
|
Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management[J]. Am J Obstet Gynecol, 2016, 215: 704-711. doi: 10.1016/j.ajog.2016.07.045 |
[11]
|
Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women[J]. Endocrine reviews, 2002, 23: 529-539. doi: 10.1210/er.2001-5002 |
[12]
|
Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial[J]. JAMA, 2003, 290: 1729-1738. doi: 10.1001/jama.290.13.1729 |
[13]
|
Ran SY, Yu Q, Chen Y, et al. Prevention of postmeno-pausal osteoporosis in Chinese women: a 5-year, double-blind, randomized, parallel placebo-controlled study[J]. Climacteric, 2017, 20: 391-396. doi: 10.1080/13697137.2017.1325459 |
[14]
|
Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women[J]. Cochrane Database Syst Rev, 2017, 1: CD004143. |
[15]
|
Botteri E, Støer NC, Sakshaug S, et al. Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway[J]. BMJ Open, 2017, 7: e17639. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5695317/ |
[16]
|
Labadie JD, Harrison TA, Banbury B, et al. Postmeno-pausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location[J]. JNCI Cancer Spectr, 2020, 4: a42. http://www.researchgate.net/publication/344253462_Postmenopausal_Hormone_Therapy_and_Colorectal_Cancer_Risk_by_Molecularly_Defined_Subtypes_and_Tumor_Location |
[17]
|
Mauvais-Jarvis F, Manson JE, Stevenson JC, et al. Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications[J]. Endocr Rev, 2017, 38: 173-188. doi: 10.1210/er.2016-1146 |
[18]
|
Javed AA, Mayhew AJ, Shea AK, et al. Association Between Hormone Therapy and Muscle Mass in Postmenopausal Women: A Systematic Review and Meta-analysis[J]. JAMA Netw Open, 2019, 2: e1910154. doi: 10.1001/jamanetworkopen.2019.10154 |
[19]
|
Venetkoski M, Savolainen-Peltonen H, Rahkola-Soisalo P, et al. Increased cardiac and stroke death risk in the first year after discontinuation of postmenopausal hormone therapy[J]. Menopause, 2018, 25: 375-379. doi: 10.1097/GME.0000000000001023 |
[20]
|
Kim JE, Chang JH, Jeong MJ, et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases[J]. Sci Rep, 2020, 10: 20631. doi: 10.1038/s41598-020-77534-9 |
[21]
|
Rovinski D, Ramos RB, Fighera TM, et al. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis[J]. Thrombosis Res, 2018, 168: 83-95. doi: 10.1016/j.thromres.2018.06.014 |
[22]
|
Scarabin PY. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis[J]. Climacteric, 2018, 21: 341-345. doi: 10.1080/13697137.2018.1446931 |
[23]
|
Shao H, Breitner JC, Whitmer RA, et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study[J]. Neurology, 2012, 79: 1846-1852. doi: 10.1212/WNL.0b013e318271f823 |
[24]
|
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial[J]. JAMA, 2002, 288: 321-333. doi: 10.1001/jama.288.3.321 |
[25]
|
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial[J]. JAMA, 2004, 291: 1701-1712. doi: 10.1001/jama.291.14.1701 |
[26]
|
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence[J]. Lancet, 2019, 394: 1159-1168. doi: 10.1016/S0140-6736(19)31709-X |
[27]
|
Gompel A, Plu-Bureau G. Progesterone, progestins and the breast in menopause treatment[J]. Climacteric, 2018, 21: 326-332. doi: 10.1080/13697137.2018.1476483 |
[28]
|
Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women[J]. Cochrane Database Syst Rev, 2016, (10): CD008536. http://www.researchgate.net/publication/309120259_Short-term_and_long-term_effects_of_tibolone_in_postmenopausal_women |
[29]
|
Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review[J]. Climacteric, 2016, 19: 316-328. doi: 10.1080/13697137.2016.1187123 |
[30]
|
Gompel A. Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy[J]. Climacteric, 2018, 21: 321-325. doi: 10.1080/13697137.2018.1446932 |
[31]
|
Vargiu V, Amar ID, Rosati A, et al. Hormone replacement therapy and cervical cancer: a systematic review of the literature[J]. Climacteric, 2020: 1-8. doi: 10.1080/13697137.2020.1826426. |
[32]
|
Beral V, Gaitskell K, Hermon C, et al. Menopausal hor-mone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies[J]. Lancet, 2015, 385: 1835-1842. doi: 10.1016/S0140-6736(14)61687-1 |
[33]
|
Pergialiotis V, Pitsouni E, Prodromidou A, et al. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis[J]. Menopause, 2016, 23: 335-342. doi: 10.1097/GME.0000000000000508 |
[34]
|
Kilander C, Lagergren J, Konings P, et al. Menopausal hormone therapy and biliary tract cancer: a population-based matched cohort study in Sweden[J]. Acta Oncol, 2019, 58: 290-295. doi: 10.1080/0284186X.2018.1549367 |
[35]
|
Zhong G, Liu Y, Chen N, et al. Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematic review and dose-response meta-analysis of observational studies[J]. Hum Reprod Update, 2016, 23: 126-138. doi: 10.1093/humupd/dmw037 |